The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer.
The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer.
复制标题
FamilyTalk 随机对照试验:患者报告的结直肠癌临床基因测序结果。
DOI:
10.1007/s10552-021-01398-1
复制
发表时间:
2021
期刊:
影响因子:
--
通讯作者:
Jarvik,GailP
中科院分区:
文献类型:
--
作者:
Makhnoon,Sukh;Bowen,DeborahJ;Shirts,BrianH;Fullerton,StephanieM;Larson,EricB;Ralston,JamesD;Leppig,KathleenA;Crosslin,DavidR;Veenstra,David;Jarvik,GailP
As genetics gains favor in clinical oncology, it is important to address patient concerns around confidentiality, privacy, and security of genetic information that might otherwise limit its utilization. We designed a randomized controlled trial to assess the social impact of an online educational tool (FamilyTalk) to increase family communication about colorectal cancer (CRC) risk and screening. Of 208 randomized participants, 149 (71.6%) returned six-month surveys. Overall, there was no difference in CRC screening between the study arms. Privacy and confidentiality concerns about medical and genetic information, reactions to genetic test results, and lifestyle changes did not differ between arms. Participants with pathogenic or likely pathogenic (P/LP) and variant of uncertain significance (VUS) results were more likely than those with negative results to report that the results accurately predicted their disease risks (OR 5.37,p= 0.02 and OR 3.13,p= 0.02, respectively). This trial demonstrated no evidence that FamilyTalk impacted patient-reported outcomes. Low power, due to the limited number of participants with P/LP results in the overall sample, as well as the short follow-up period, could have contributed to the null findings.